Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | ponatinib (Iclusig®) | ||
| Formulation | 15 mg and 45 mg film-coated tablet | ||
| Reference number | 1163 | ||
| Indication | Treatment of adult patients with: chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation; or Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation |
||
| Company | ARIAD Pharma UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 3714 | ||
| NMG meeting date | 15/10/2014 | ||
| AWMSG meeting date | 12/11/2014 | ||
| Ratification by Welsh Government | 09/01/2015 | ||
| Date of issue | 13/01/2015 | ||
| NICE guidance | TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
||